Spectrum of Pharmacological Activity of Monoclonal Antibodies-Reference-Cited by-同舟云学术

Spectrum of Pharmacological Activity of Monoclonal Antibodies

Published:2019-09-01 Issue:5 Volume:4 Page:17-32
ISSN:2415-3060
Container-title:Ukraïnsʹkij žurnal medicini, bìologìï ta sportu
language:
Short-container-title:Ukr. ž. med. bìol. sportu

Author:

Zaychenko A. V., ,Gorchakova N. A.,Shumeiko O. V.,Klymenko O. V.,Khodakivska O. V.

Publisher

Petro Mohyla Black Sea National University

Reference96 articles.

1. Nelson AL, Dhimolea E, Reichert JM. Development trends for human monoclonal antibody therapeutics. Nature reviews drug discovery. 2010; 9(10): 767-74. https://www.ncbi.nlm.nih.gov/pubmed/20811384. https://doi.org/10.1038/nrd3229

2. Mel'nik AA. Primenenie immunobiologicheskih lekarstvennyh preparatov na osnove monoklonal'nyh antitel v nefrologicheskoj praktike. Pochki. 2018; 7(3): 224-36. [Russian]

3. Bernett MJ, Karki S, Moore GL, Leung IW, Chen H, Pong E, Desjarlais JR. Engineering fully human monoclonal antibodies from murine variable regions. Journal of molecular biology. 2010; 396(5): 1474-90. https://www.ncbi.nlm.nih.gov/pubmed/20045416. https://doi.org/10.1016/j.jmb.2009.12.046

4. Lin W, Kurosawa K, Murayama A, Kagaya E, Ohta K. B-cell display-based one-step method to generate chimeric human IgG monoclonal antibodies. Nucleic acids research. 2010; 39(3): e14. https://www.ncbi.nlm.nih.gov/pubmed/21062829. https://www.ncbi.nlm.nih.gov/pmc/articles/3035438. https://doi.org/10.1093/nar/gkq1122

5. Harding FA, Stickler MM, Razo J, DuBridge R. The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions. MAbs. 2010; 2(3): 256-65. https://www.ncbi.nlm.nih.gov/pubmed/20400861. https://www.ncbi.nlm.nih.gov/pmc/articles/2881252. https://doi.org/10.4161/mabs.2.3.11641